Hill-Rom Holdings Inc (NYSE:HRC) was downgraded by research analysts at ValuEngine from a “buy” rating to a “hold” rating in a report issued on Saturday.

Other analysts have also recently issued reports about the stock. KeyCorp reaffirmed a “buy” rating and set a $82.00 price objective on shares of Hill-Rom Holdings in a research note on Tuesday, October 17th. Needham & Company LLC decreased their price objective on shares of Hill-Rom Holdings from $95.00 to $93.00 and set a “buy” rating on the stock in a research note on Friday, July 28th. BidaskClub cut shares of Hill-Rom Holdings from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 24th. Stifel Nicolaus reaffirmed a “buy” rating and set a $84.00 price objective on shares of Hill-Rom Holdings in a research note on Sunday, July 30th. Finally, Zacks Investment Research raised shares of Hill-Rom Holdings from a “hold” rating to a “buy” rating and set a $90.00 price objective on the stock in a research note on Friday, October 27th. Three research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Hill-Rom Holdings has an average rating of “Buy” and a consensus price target of $87.29.

Shares of Hill-Rom Holdings (NYSE HRC) traded down $3.39 during trading on Friday, hitting $77.50. 1,219,951 shares of the stock were exchanged, compared to its average volume of 446,033. The stock has a market capitalization of $5.27 billion, a PE ratio of 21.50, a P/E/G ratio of 1.65 and a beta of 1.19. The company has a debt-to-equity ratio of 1.67, a current ratio of 1.76 and a quick ratio of 1.33.

Hill-Rom Holdings (NYSE:HRC) last posted its earnings results on Friday, November 3rd. The medical technology company reported $1.32 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.27 by $0.05. The business had revenue of $738.30 million for the quarter, compared to analysts’ expectations of $731.10 million. Hill-Rom Holdings had a net margin of 4.27% and a return on equity of 19.99%. The firm’s revenue for the quarter was up 4.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.18 earnings per share. analysts expect that Hill-Rom Holdings will post 3.82 earnings per share for the current fiscal year.

WARNING: This article was originally published by American Banking News and is owned by of American Banking News. If you are reading this article on another publication, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The legal version of this article can be viewed at https://www.americanbankingnews.com/2017/11/04/hill-rom-holdings-inc-hrc-lowered-to-hold-at-valuengine.html.

In other news, SVP Andreas G. Frank sold 6,870 shares of the stock in a transaction that occurred on Thursday, September 14th. The shares were sold at an average price of $77.48, for a total transaction of $532,287.60. Following the sale, the senior vice president now directly owns 16,701 shares of the company’s stock, valued at $1,293,993.48. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Andreas G. Frank sold 3,940 shares of the stock in a transaction that occurred on Wednesday, September 13th. The shares were sold at an average price of $77.84, for a total transaction of $306,689.60. Following the sale, the senior vice president now directly owns 16,701 shares in the company, valued at $1,300,005.84. The disclosure for this sale can be found here. 2.20% of the stock is currently owned by corporate insiders.

Several institutional investors and hedge funds have recently added to or reduced their stakes in HRC. Independent Portfolio Consultants Inc. grew its stake in shares of Hill-Rom Holdings by 171.5% during the second quarter. Independent Portfolio Consultants Inc. now owns 1,344 shares of the medical technology company’s stock valued at $107,000 after purchasing an additional 849 shares during the last quarter. Seven Eight Capital LP bought a new stake in shares of Hill-Rom Holdings during the second quarter valued at approximately $127,000. Acrospire Investment Management LLC grew its stake in shares of Hill-Rom Holdings by 43.4% during the second quarter. Acrospire Investment Management LLC now owns 1,983 shares of the medical technology company’s stock valued at $158,000 after purchasing an additional 600 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of Hill-Rom Holdings by 10.2% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,201 shares of the medical technology company’s stock valued at $175,000 after purchasing an additional 204 shares during the last quarter. Finally, Citigroup Inc. grew its stake in shares of Hill-Rom Holdings by 21.1% during the second quarter. Citigroup Inc. now owns 2,483 shares of the medical technology company’s stock valued at $198,000 after purchasing an additional 433 shares during the last quarter. 82.44% of the stock is currently owned by institutional investors and hedge funds.

Hill-Rom Holdings Company Profile

Hill-Rom Holdings, Inc is a global medical technology company. The Company operates through four segments: North America Patient Support Systems, International Patient Support Systems, Front Line Care and Surgical Solutions. The Company’s products and services include Patient Support Systems, Front Line Care and Surgical Solutions.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Hill-Rom Holdings (NYSE:HRC)

Receive News & Ratings for Hill-Rom Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom Holdings Inc and related companies with MarketBeat.com's FREE daily email newsletter.